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Ahatrac-Problems with self-report measures for smoking motivate the use of biochemical tests 
in treatment trials for smoking. These biochemical tests, unfortunately, am not perfect. In this 
paper, we present an algebraic model of bias in treatment trials for smoking. Bias is expressed in 
terms of the deception rate among continued smokers in a control group, the relative deception 
rate among continued smokers in an experimental group, and the sensitivity and specificity of a 
biochemical test which may be used either to co&m self-reports of ,quitting or to replace 
self-report entirely. For given test specificity and sensitivity, the model defines deception rates for 
which different biochemical testing strategies are preferred. The model is presented in the context 
of current knowledge on the phenomenon of deception among adult smokers. The paper concludes 
that better judgements regarding the role of biochemical tests in treatment trials for smoking 
require more precise information regarding the magnitude and determinants of deception. 
Smoking Tntth disclosure Models theoretical Research design 
INTRODUCTION 
The methods of the randomized, controlled, 
clinical trial have been employed to determine 
whether varied treatments help smokers quit. A 
self-report of quitting represents the most direct 
measure of the outcome of such treatments. 
However, studies suggest that a smoker may not 
accurately report his true smoking behavior 
[l-19]. Further, a smoker who has knowingly 
received a special, intensive, or otherwise experi- 
mental treatment for smoking may be more 
inclined to misrepresent his smoking [20]. 
Within the context of a clinical trial, where 
unobtrusive or blinded smoking cessation inter- 
ventions are difhcult to implement, the greatest 
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concern is that biased self-reports may produce 
an apparent treatment e&ct where none, in fact, 
exists [2 11. 
This concern forms the basis for the use of 
biochemical measures as an outcome for clinical 
trials which examine treatments for smoking 
1223. Usually, biochemical tests are used to 
con&m the reports of those who say they have 
quit. Unlike self-report, the veracity of bio- 
chemical tests are independent of subjects’ 
knowledge of the treatments delivered. Any test, 
however, will misclassify some quitters and con- 
tinued smokers. Investigators will generally ac- 
cept misclass&ttion of some quitters, as a 
consequence of testing strategies which correctly 
identify all or most smokers. In the context of 
a clinical trial; this is a conservative strategy; as 
we will show, it is designed to prevent biased 
self-report from giving the false appearance of 
treatments with I different effects. We will also 
show that, when subjects are relatively truthful 
in their self-reports, a testing strategy which 
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favors identification of continued smoking will 
more severely underestimate any real difference 
among treatments. 
This paper presents a model which quantifies 
bias in the results of a clinical trial. Bias results 
from deception by continued smokers in the 
experimental and control groups and from im- 
perfections in biochemical tests used to detect 
deception. From this model, we derive equa- 
tions which express the conditions under which 
different uses of biochemical tests appear more 
or less appropriate. 
average, smoke less heavily, abstain for longer 
durations before a scheduled collection of bio- 
logical samples for assay, inhale less deeply, or 
switch to cigarettes with lower nicotine yields. 
BACKGROUND 
Sensitivity and speciJicity of biochemical tests for 
smoking 
None of the current biochemical measures for 
smoking is perfect. Concentrations of carbon 
monoxide in exhaled air, carboxyhemoglobin in 
blood, and thiocyanate, nicotine, and cotinine 
in blood, saliva, and urine, distinguish smokers 
and nonsmokers. Assays for these substances 
vary with respect to sensitivity, specificity, cost, 
ease of automation, and suitability for large 
scale field studies. Using populations presumed 
to have “no reason” to misrepresent smoking 
status, previous studies [3, 10, 11,23-251 of 
the validity of these measures compare either 
one measure against a second or one measure 
against self-report. Thus, a test, validated 
against self-report in one setting, is often used 
to detect deceptive self-reports in another set- 
ting. This contributes to the uncertainty which 
surrounds quantification of deceptive self- 
report. 
Biochemical measures of smoking are more 
or less susceptible to losses in specificity which 
result from a variety of environmental ex- 
posures [26,27]. Specificity is defined as the 
proportion of true nonsmokers who are 
classified as nonsmokers by the biochemical 
test. All measures are susceptible to errors 
which result from failure to account for pipe, 
cigar, and passive smoking. Assessments of 
exhaled carbon monoxide and blood carboxy- 
hemoglobin are particularly susceptible to 
exposures from occupational sources, air pollu- 
tion, or faulty home heating. Assessments of 
thiocyanate are susceptible to variation in 
dietary intakes of cyanide and thiocyanate. 
Assessments of nicotine and cotinine must 
account for usage of smokeless tobacco and 
nicotine containing chewing gum. Of particular 
interest are exsmokers who require medical care 
for a chronic condition related to smoking or 
who quit smoking as a result of an experimental 
intervention. They may differ from the groups 
of nonsmokers typically used to establish the 
specificity of biochemical measures of smoking. 
Such exsmokers, for example, may have greater 
exposures to passive smoke, environmental 
sources of carbon monoxide, or even dietary 
sources of thiocyanate. Each of these exposures 
potentially lowers the specificity of a biochem- 
ical test. 
All the biochemical measures lose sensitivity 
at lower levels of smoking [23,24]. Sensitivity is 
defined as the proportion of true smokers who 
are classified as smokers by the biochemical test. 
In addition, the substances assayed have 
different biological half-lives [22]. These bio- 
chemical measures are more or less susceptible 
to losses in sensitivity which result from longer 
durations since last cigarette (which correlate, in 
turn, with lower levels of smoking) [25]. Smok- 
ers who participate in studies designed to assess 
the sensitivity of biochemical tests may differ in 
important ways from smokers who participate 
in clinical trials. These differences may be exag- 
gerated among clinical trial participants who 
falsely report quitting, the subgroup for which 
biochemical tests are generally intended. For 
example, smokers in an experimental group or 
smokers who falsely report quitting may, on 
Few studies assess all the customary biochem- 
ical measures of smoking on a single group of 
subjects. The study by Jarvis et al. [6] is an 
exception. This study assessed all measures 
on 211 patients attending a cardiology or 
peripheral vascular disease clinic. Twenty-one 
professed nonsmokers, with very high plasma 
cotinine levels, were reclassified as smokers. 
When subjects were subsequently classified by 
cutoffs which yielded 95% specificity for each 
assay, sensitivities, for detection of all smokers, 
ranged between 25% (for saliva thiocyanate) 
and 98% (for urinary cotinine). Thus, different 
biochemical measures are imperfect and differ 
with respect to sensitivity (for given specificity). 
We argue that comparison of biochemical 
tests can involve criteria in addition to sensi- 
tivity and specificity. Tests with differences in 
sensitivity and specificity (and associated 
differences in cost or ease of administration) can 
be evaluated in the context of the magnitude of 
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deception which threatens the validity of clinical 
trials for smoking. 
Deception 
Several factors, in theory, influence deception 
rates. The pressure to under-report smoking 
derives from the social undesirability of smok- 
ing, from threats to self-confidence or self-image 
which result from failure to quit smoking, or 
from wishes to please counselors or experi- 
menters with whom smokers engage. In some 
studies, participants are intentionally made 
aware of plans to use a biochemical assay to 
validate self-reports, in the hope that this so- 
called “bogus pipeline” imbroves the accuracy 
of self-report [28]. Hypothetically, the bogus 
pipeline can be imagined to work in “reverse”. 
For example, some nonsmokers, made aware 
that self-reports of nonsmoking are subject to 
biochemical confirmation, may be prompted to 
report, falsely, that they smoke. Such a tendency 
might result from concern over the incon- 
venience associated with the collection of the 
biological sample or from the fear that biologi- 
cal fluid, so collected, might be used for some 
unspecified, unapproved, or undesired purpose 
(e.g. illicit drug screening or AIDS testing). 
Finally, apparent deception among continued 
smokers who report not smoking may not 
represent deception, as such, but rather inade- 
quacy of the survey measure used to assess 
smoking status [29]. The point, here, is that a 
number of factors are capable of influencing the 
proportion of smokers who appear to 
falsely report not smoking. Moreover, many 
of these factors are amenable to control by 
investigators. 
With thisdiscussion as background, Tables l-3 
summarize previous investigations which enable 
an estimate of deception rates. Table 1 sum- 
marizes five studies which examine either 
general population samples, individuals who 
consent to health screening examinations, or 
members of an occupational group [l-5]. Esti- 
mates for the deception rate, the proportion of 
smokers who deny smoking, range between 0.6 
and 7.8%. Some of this variation probably 
derives from variation in biochemical measures 
and associated cutoffs used to identify deceptive 
self-reports among professed nonsmokers. In 
general, these studies employ test combinations 
and cut-off values expected to-produce relatively 
specific measures for smoking. Thus, the 
deception rates suggested by the studies cited in 
Table 1 cannot be simply attributed to falsely 
positive test results in a largely nonsmoking 
Table 1. Deception rates inferred from community surveys, occupational surveys, or health screening studies 
Cutoff used to 
distinguish smoker Deception 
Source Biochemical measure. from nonsmoker Sample size* rate (d) 
Fortmann er al. (1984) [l] Exhaled carbon monoxide 8ppm 380 0.0316 
and serum thiocyanate 
Pierce et al. (1987) [2] 
100 rmol/l 
Saliva cotinine 44 n8ln-d 622 0.0402 
Wald et al. (1981) [3] Serum c&oxyhemoglobin 3% 2095 0.0060 
Cohen and Bartsch (1980) [4] Serum t+iocyanate 150 pmol/l 438 0.0274 
Carboxyhemoglobin 2% 462 0.0779 
Carboxyhemoglobin 3% 443 0.0384 
Robertson et al. (1987) [S] Serum thiocyanate 70 gmol/l 54 0.0556t 
and exhaled carbon monoxide 10 ppm 
*Self-reported quitters with a positive biochemical test for smoking and all self-reported smokers. 
tIncludes two self-reported nonsmokers who confess smoking when challenged with elevated thiocyanate results. 
Table 2. Deception rates inferred from patients selected from clinical populations 
Cutoff used to 
distinguish smoker Deception 
Source Biochemical measure from nonsmoker Sample size* rate (d) 
Jarvis et al. (1987) [6] Serum c&nine 50 ng/ml 111 0.189 
Ronan et af. (1981) [7] G&oxyhemoglobin 1.6% 40 0.125 
Sillett et of. (1978) [8] Carboxyhemoglobin 1.6% 0.282 
Vesney et al. (1985) [9] Serum thiocyanate and 70 rmol/l z 0.125 
carboxyhemoglobin 
Wilcox et al. (1979) [lOI Urine nicotine or 202;ml 44 0.182 
urine c&nine 10 ng/ml 
*Self-reported quitters with a positive biochemical test for smoking and all self-reported smokers. 
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Table 3. Deception rates inferred from subjects enrolled in stop smoking clinics or smoking cessation treatment trials. 
cutoff used to 
distinguish smoker Deception 
source Biochemical measure from nonsmoker Sample size* rate (d) 
Abrams et al. (1987) [I I] Saliva cotinine 10 ng/ml 81 0.0123 
4 0 
Colletti er al. (1982) [12] Exhaled carbon monoxide 10 ppm 15 0.1333 
(four separate studies) 14 0 
28 0 
Glynn ef al. (1986) [13] Exhaled carbon monoxide 10 ppm 36 0.194 
Jamrozik et al. (1984) [14] Urinary cotinine 100 ng/ml 51 0.216 
Lando, (1975) Exhaled carbon monoxide 11 PPm 8 0 
Ohlin et al. (1976) [15] Carboxyhemoglobin 0.8% 209 0.167 
Russell et al. (1976) [16] Carboxyhemoglobin 3.7% 20 0.050 
Sillett et al. (1978) [17] Carboxyhemoglobin 1.6% 91 0.363 
Stookey et al. (1987) [18] Saliva cotinine 10 ng/ml 262 0.149 
Exhaled carbon monoxide 8 ppm 262 0.084 
Walker and Franzini (1985) [19] Exhaled carbon monoxide 8 ppm 49 0 
*Self-reported quitters with a positive biochemical test for smoking and all self-reported smokers. 
population (i.e. individuals who report not 
smoking). 
Table 2 summarizes five studies which enable 
calculation of a deception rate among smokers 
examined in the context of a physician visit for 
illnesses associated with cigarette smoking 
[6-lo]. Deception rates range between 12.5 and 
28.2%. Though some employ slightly less 
specific measures for smoking, these studies 
clearly indicate the potential for deception 
among this select group of smokers. 
Table 3 summarizes 10 studies which enable 
calculation of deception rates among subjects 
completing defined treatments for smoking 
[l l-191. Calculated deception rates range be- 
tween 0 and 36.3% (weighted average 14.9%, 
sample size 868). Only one study specifically 
delivered treatments in the context of the care 
provided by physicians [ 141. These studies exam- 
ine treatments which vary widely in intensity, 
duration, nature of subject-experimenter con- 
tacts, and conditions under which self-reports 
are obtained. 
In summary, available data suggest low de- 
ception rates (less than 8%) among participants 
of community survey or health screening exams, 
high rates (approximately 20%) among patients 
visiting doctors’ offices, and widely varying rates 
among subjects completing an experimental 
treatment for smoking. Unfortunately, very few 
studies compare deception rates between groups 
of smokers who complete experimental and 
control treatments for smoking. The Multiple 
Risk Factor Intervention Trial (MRFIT) did 
employ a relatively nonspecific measure of 
smoking, blood thiocyanate, to adjust self- 
reported cigarette smoking quit rates, in both 
experimental and control groups [20]. Decep- 
tion rates were estimated from observed and 
expected serum thiocyanate levels, the latter 
adjusted for diuretic, pipe, and cigar use. Decep- 
tion rates in the control (Usual Care) group 
ranged between 1.2 and 3.0% (depending on 
duration of follow-up). Corresponding decep- 
tion rates in the experimental (Special Inter- 
vention) group ranged between 8.8 and 17.2%. 
Estimated deception rates in the Special Inter- 
vention group may be inflated. The regression 
methods used to calculate expected thiocyanate 
levels disregard the fact that cigarette smokers 
w,ho switch to cigars or pipes (which may have 
occurred at a higher rate in the Special Inter- 
vention group) have higher thiocyanate levels 
than cigar or pipe smokers who have never 
smoked cigarettes [30]. Special Intervention par- 
ticipants, as well, received concomitant dietary 
treatments aimed at reducing serum cholesterol. 
The effects of induced dietary changes on levels 
of thiocyanate are uncertain. However, the 
results of MRFIT provide, at least, an upper 
bound on the expected enhancement in 
deception among smokers who receive an 
experimental treatment for smoking. 
DESCRIPTION OF THE MODEL 
Dejinitions and asmmptio~s 
We derive equations which express the bias in 
a clinical trial produced by deception among 
continued smokers, by enhanced deception 
among continued smokers who receive an ex- 
perimental treatment, and by errors in a bio- 
chemical test administered to none, some, or all 
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participants in the trial. For this purpose, we 
define 
P,, the true quit rate in the experimental 
group (i.e. the proportion of subjects in 
the experimental group who truly quit 
smoking); 






(i.e. the proportion of subjects in the 
control group who truely quit smoking); 
the deception rate among continued 
smokers in the control group (i.e. the 
proportion of continued smokers in 
the control group who falsely report 
quitting); 
a factor which represents enhanced de- 
ception by continued smokers in the 
experimental group; 
the proportion of continued smokers in 
the experimental group who falsely 
report quitting; 
the specificity of the biochemical test for 
smoking (i.e. the proportion of true non- 
smokers identified as nonsmokers by the 
biochemical assay; 
the sensitivity of the biochemical test for 
smoking (i.e. the proportion of true 
smokers identified as smokers by the 
biochemical assay). 
We assume that the sensitivity and specificity 
of the test are independent of both treatment 
category and self-reported smoking status. Fur- 
ther, we assume that the experimental treatment 
is at least as effective as the control treatment 
(i.e. P, >, PO). Finally, we assume that all 
subjects, who truly quit smoking, report that 
they have quit. 
The true treatment effect is the differenoe 
between the quit rates in the experimental and 
control groups (i.e. P, - PO). The absolute bias 
is the difference between the observed treatment 
effect and the true treatment effect. Finally, the 
relative bias is the ratio between the bias and the 
true treatment effect. 
PROPERTIES OF THE MODEL 
Basic relationships 
An algebraic model is used to derive expres- 
sions for bias when trial outcomes are defined 
by self-report alone, biochemical test results 
alone, and a combination of self-report and 
biochemical test results. We derive these expres- 
sions in Appendix A. The relative bias, under 
conditions of self-report, is 
d*(fW',)-V-P,)). 
p, - PO 
(1 A5) , 
When the biochemical test is used to classify all 
participants, the relative bias is 
- ((1 - SJ + (1 - Se)). (2, AlO) 
Finally, when the test is only used to classify 
self-reported quitters, the relative bias is 
d*(f(l -P,)-(1 -P,,)s- (1 - Sp). 
I 0 
(3, Al3) 
Several generalizations result directly from 
these expressions. 
Case I: P, = PO = P. In the absence of a true 
treatment effect (i.e. P, = PO = P), one can ex- 
amine the absolute, but not the relative, bias. 
Expressions for the absolute bias are found in 
Appendix A (expressions A4, A9, and A12). 
When P, = PO = P, the absolute bias, in a trial 
which classifies subjects by self-report, is 
d(l - P)(f - 1). (4, from A4) 
From expression (A9), we conclude that a trial 
is not biased when a test, no matter how imper- 
fect, is used to classify all subjects. The absolute 
bias, in a trial which classifies only self-reported 
quitters according to test results, is 
d(1 - P)(f - I)(1 - S,). (5, from A12) 
Therefore, in the absence of a treatment 
effect, the study is not biased if a biochemical 
test classifies all su ‘ects (expression A9). 
(Unless deception rat 
1 
are identical among 
experimental and contr 1 subjects, f = 1, expres- 
sion 5), administratio of a biochemical test 
only to self-reported quitters always biases the 
trial in favor of the experimental treatment. In 
this latter case, the degree to which the assay 
reduces the bias (relative to self-report alone) 
depends only on the sensitivity of the assay. 
Finally, we note that in the absence of a true 
treatment effect, use of a test with imperfect 
specificity does not bias the results of the trial. 
Case II: d = 0; P, 2 PO. In the absence of 
deception (i.e. d = 0), it follows from expression 
(1) that a trial which relies solely on self-report 
is not biased. 
However, a trial which classifies all par- 
ticipants according to an imperfect test (i.e. 
S, < 1 and or S, < 1) has a relative bias which 
is the negative of the sum of the “false positive” 
(1 - S,) and “false negative” (1 - S,) rates 
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(expression 2). A negative relative bias reduces 
the apparent magnitude of a true treatment 
effect. Here, we assume that the sum of the 
sensitivity and specificity is greater than one. 
This implies that the test discriminates between 
smokers and nonsmokers in the direction 
intended by those who make use of the test. 
When the test is used to classify self-reported 
quitters only, a relative bias exists only if the test 
has imperfect specificity. Here, the relative bias 
is the negative of the “false positive” rate, i.e. 
-(l - S,) (from expression 3). 
Case III: f = I; P, > P,. In the absence of 
enhanced deception among continued smokers 
who receive an experimental intervention 
(f = 1), expression (1) the relative bias when 
the test is not used, becomes 
-d, (6) 
the negative of the deception rate among smok- 
ers in the control group. Expression (2), the 
relative bias when testing all subjects, does not 
change. Expression (3), the relative bias associ- 
ated with testing self-reported quitters alone, 
reduces to 
-(d(l - S,) + (1 - S,)). (7) 
Thus, under these conditions (Case III), the 
relative bias, is always negative. That is, whether 
the test is administered to none, all subjects, or 
self-reported quitters only, a negative bias re- 
duces the apparent magnitude of a true treat- 
ment effect. These three settings vary only with 
respect to the magnitude of this negative relative 
bias. The relative bias is less (in absolute value) 
when the test is administered to all participants 
(relative to no testing at all) when 
1 expression (2) I < 1 expression (6) 1, 
I-((l-~,)+(l-~,))I<I-dl, 
or 
(1 -S,)+(l -S,)<d, (8) 
(i.e. when the sum of the “false positive” and the 
“false negative” rates is less than the deception 
rate). The relative bias is less (in absolute value) 
when the test is administered to only self- 
reported quitters (relative to no testing at all) 
when 




2 < d, n (9) 
(i.e. when the ratio between the “false positive” 
rate and the sensitivity (“true positive” rate) is 
less than the deception rate). Finally, the rela- 
tive bias is always less when self-reported quit- 
ters, instead of all participants, are tested (i.e. 
17 d((1 -S,) + (1 - S,))l is always less than 
I - ((1 - S,) + (1 - S,))l). Thus, when decep- 
tion is equivalent among experimental and con- 
trol groups (i.e. f = l), a trial which classifies 
subjects by the results of an imperfect test 
remains biased in a direction against the true 
treatment effect. The false positive and false 
negative rates (when all subjects are tested; 
expression 8) and the false positive rate (when 
only self-reported quitters are tested; expression 
9) must be small relative to the deception rate if 
testing is to diminish the relative bias which 
exists by virtue of deception alone. 
Summary. These special cases are easily 
summarized (see Table 4). In the presence of 
equivalent treatments (Case I), deception and 
enhanced deception produce a bias, unless all 
subjects are classified by the results of a bio- 
chemical test. The trial is biased in favor of the 
Table 4. Expected direction of bias in the results of a clinical treatment trial for smoking. 
Results are shown for three alternative means of determining outcome and under four modeled 
conditions 
Case 
Conditions Outcome assessment 
Treatment Test self-reported Test all 
effects Deception Self-report quitters subjects 
I Equal Present, enhanced + + 0 
II %qZI 
(d 2,;;;Y; i) 
0 - 
(PI ’ PO) (d = 0) 
III Unequal Present, not enhanced - 
(PI ’ PO) (d >O,f= I) 
General Unequal Present, enhanced + ** - 
case (PI ’ PO) (d>O,f> I) 
0 = no bias; + = positive bias; - = negative bias. 
*Depends on the ratio between the false positive and false negative rates (expression 10). 
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experimental treatment. Testing self-reported 
quitters lessens the magnitude of the bias by a 
factor equal to the false negative rate (1 - S,). 
In the absence of deception (Case II), a trial 
which uses an imperfect test to confirm self- 
reported smoking status is biased against obser- 
vation of a treatment effect. The bias is larger if 
the test is used to classify all subjects (relative to 
self-reported quitters only). Finally, the absence 
of enhanced deception among continued smok- 
ers who receive the experimental intervention 
(Case III: f = l), a trial is always biased against 
observation of the treatment effect. Whether a 
confirmatory test increases or decreases (relative 
to no testing) the magnitude of the bias depends 
on the relationship between test characteristics 
(i.e. S,,, S,) and the deception rate (d). Again, 
the bias is larger when the test is used to classify 
all subjects (relative to self-reported quitters 
alone). 
The general case 
We now consider the general case, treatments 
with different effects (P, -PO > 0), deceptive 
self-report (0 < d < l), and enhanced deception 
within the experimental group (f > 1; see 
Table 4, general case). When outcomes are 
based solely on self-report, the trial is biased 
in favor of the experimental treatment (expres- 
sion 1). When outcomes are based solely on 
biochemical test results, the trial is biased 
against the experimental treatment (expres- 
sion 2). In addition, the sensitivity and 
specificity appear to have equivalent effects on 
the magnitude of the relative bias. 
When the biochemical test is used only to 
classify self-reported quitters, the trial can be 
biased in either direction, depending on the 
relative magnitudes of the false negative (1 - S,) 
and false positive (1 - S,) rates (expression 3). 
Here, deterioration in sensitivity produces 
progressive bias in a positive direction. Deterio- 
ration in specificity has an effect in the opposite 
direction. Rearranging expression (3), set to 
values less than zero, we conclude that the 
relative bias is not positive as long as 
1-S 
j--+&$fU -P,)--(1 -Pd. wo 
That is, this is the condition under which decep- 
tion will not, at least, exaggerate the apparent 
effectiveness of the ‘experimental treatment. 
Some representative values for d, ft P,, and PO 
illustrate the properties of this inequality. 
Suppose P,=O.2, PO=O.l, d=O.l, andf 12. 
Under these conditions, a clinical trial which 
tests self-reported quitters is unbiased if 
(1 - SJ(1 - S,) = 0.7, biased in a negative 
direction if (1 - S,,)/( 1 - S,) > 0.7, and biased 
in a positive direction if (1 - SJ(1 - S,) < 0.7. 
Suppose the biochemical test for smoking 
misclassifies 10% of true nonsmokers as smok- 
ers (i.e. 1 - S, = 0.1). Then, this test need only 
achieve a sensitivity of 0.857 (i.e. 1 - 0.1/0.7) in 
order to guarantee a trial not biased in a 
positive direction. 
The demands on the sensitivity of the test 
increase as d and/or f increases. Suppose the 
deception rate is 0.3 instead of 0.1. Here, a trial 
which tests self-reported quitters is unbiased if 
(1 - S,)/( 1 - S,) = 2.1 and is negatively biased 
if (1 - S,)/(l - S,) > 2.1. When S, = 0.9, the 
same value used above, S, must exceed 0.952 to 
guarantee a trial not positively biased. 
Thus, when sensitivity or specificity are not 
perfect, we can find the point beyond which 
improvement in test sensitivity (for a given 
test specificity) results in progressive bias in a 
negative direction. 
The eflect of deception rates on the relative bias 
A clinical trial estimates, quantitatively, the 
degree to which an experimental treatment for 
smoking enhances smoking cessation. In the 
presence of biased self-report and/or imperfect 
biochemical confirmatory tests for smoking, this 
estimate, in general, is biased. Depending on the 
magnitude of deception (d) and enhanced 
deception in the experimental group (f ), 
classification of treatment outcomes according 
to the results of a biochemical test may or may 
not decrease this bias. Again, depending on the 
values for d and f, alternative testing strategies 
(e.g. testing only self-reported quitters vs testing 
all subjects) may affect bias differently. 
In Figs l-3, we compare, pairwise, three 
strategies for classification of outcomes: (1) 
self-reports only (strategy A), (2) biochemical 
test results only (strategy B), and (3) self-reports 
with biochemical testing restricted to self- 
reported quitters (strategy C). These three stra- 
tegies form three paired comparisons. In Fig. 1, 
a trial which uses self-report is compared with 
a trial which uses biochemical testing uniformly. 
In Fig. 2, a trial which uses self-report is com- 
pared with a trial which confirms the reports of 
self-reported quitters. In Fig. 3, a trial which 
uses biochemical testing uniformly is compared 
with a trial which confirms the reports of 
self-reported quitters. 
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Self-report (A) vs universal biochemical testing (B) 
Design least Direction of bias under 
biased in 
Region absolute value design A design B 
I B + 
II A + 
III A - 
IV B - 
01 ‘, I I I I I I I , 1 
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 
Deception rate [d] 
Fig. I. Effect of deception rates on the expected relative bias. The figure shows four regions defining values 
for d andf. Each region is unique with respect to the relative magnitudes (in absolute value) and direction 
of biases produced by two designs: outcomes classified solely by self-report (design A) and solely by 
biochemical test results (design B). The figure shows modeled results for P, = 0.4, PO = 0.1, S, = 0.9, and 
s, = 0.9. 
Self-report (A) vs selective biochemical testing (C) 
Design least Direction of bias under 
biased in 
Region absolute value design A design C 
I + + 
II : + - 




I I I 1 I I I I I 
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 
Deception rate [d] 
Fig. 2. Effect of deception rates on the expected relative bias. The figure shows five regions defining values 
for d andf. Each region is unique with respect to the relative magnitudes (in absolute value) and direction 
of biases produced by two designs: outcomes classified solely by self-report (design A) and by a 
combination of self-report among self-reported smokers and of biochemical test results among self- 
reported quitters (design C). The figure shows modeled results for P, = 0.4, PO = 0.1, S, = 0.9, and 
s, = 0.9. 
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Universal (B) vs aeleiztive biochemical testing (C) 
D$aign laaat Direction of biaa under 
biased in 
Region a absolute value design B deaign C 
I- 
O 1 I 8 I I I I I I I 
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.6 0.9 1 
Deception rate [d] 
Fig. 3. Effect of deception rates on the expected relative bias. The figure shows three regions defining values 
for d andf: Each region is unique with rcspsct to the relative magnitudes (in absolute value) and direction 
of bias produced by two designs; outcomes class&d solely by biochemkA test results (design B) and by 
a combination of self-report among self-reported smokers and of biochemical test results among 
self-reported quitters (design C). The figure shows modeled results for P, = 0.4, PO = 0.1, S; = 0.9, and 
s, = 0.9. 
Each figure depicts three to five regions. Each 
region designates. a range of values for d, the 
deception rate, andf, the factor by which decep- 
tion is enhanced in the experimental group. 
Within a given region, Figs l-3 indicate which 
of the two strategies .undergoing comparison js 
least biased (bias closest to zero). In theory, the 
deception rate d, a proportion, .may assume 
values between 0 and 1. The factor f, again in 
theory, may assume values between 0 and d-’ 
(i.e. 0 <<fad Q 1). For this reason, the upper 
right hand portions of Figs l-3 (i.e. f > d-l) are 
not defined by the model. Values for f between 
0 and 1 represent conditions when continued 
smokers in the experimental group are less ,likely 
to provide an incorrect self-report of non- 
smoking. Figures l-3 indicate, as well, the 
direction of bias produced by each strategy, 
when operating under the conditions specified 
by a given region. Trials with positive 
and negative bias overestimate and under- 
estimate,~respectively, the difference between the 
experimental and control treatments. 
The curves, which divide Figs 1-3 into n- 
gions, define values for d and f for which two 
strategies have equal bias. These curves derive 
from inequalities which employ expressions (l), 
(2), and (3) (Appendix B). These curves depend 
on the quit rates in the control (PO) and experi- 
mental (P,) groups and on the sensitivity (S,) 
and specificity+ (se) of the biochemical test for 
smoking. The specific curves in Figs l-3 illus- 
trate findings for ‘PO = 0.1, P, = 0.4, S, = 0.9, 
and S, a 0.9, 
In Fig. 1, the comparison between self-report 
(strategy A) and universal biochemical testing 
(strategy B) defines four regions. Strategy ,B 
produces the smallest relative bias when the 
deception rate d and the enhanced deception 
factor f fall into regions I or IV. Strategy A 
produces the smallest relative bias within re- 
gions II and III. Within region II, the relative 
bias is positive under designs which use self- 
report, but negative under designs which use 
universal biochemical testing. In region II, the 
“preferred” strategy depends on whether it is 
regarded as more important to minimize bias 
or to guarantee against overestimation of the 
treatment effect (i.e. positive bias). 
In Fig. 2, the comparison between self-report 
(strategy A) and selective biochemical testing 
(strategy C) defines five regions. Except within 
regions III and IV, the selective test use strategy 
produces the smallest relative bias. Within re 
gion I, the relative bias is positive whether the 
trial design uses self-report or selective bio- 
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chemical testing. Within region III, use of self- 
report results in a positive bias; selective test use 
produces a negative bias. Again, within region 
III, the “preferred” strategy depends on 
whether one wishes to minimize bias or to 
prevent positive bias. 
In Fig. 3, the comparison between universal 
(strategy B) and selective (strategy C) testing 
strategies results in three regions. Except within 
region III, selective testing produces the trial 
with the smallest relative bias. Within region I, 
the relative bias is positive under strategy B and 
negative under strategy C. Again, under the 
conditions specified within region I, the “pre- 
ferred” strategy depends on whether one prefers 
to minimize bias or to prevent positive bias. 
The curves which divide Figs l-3 into regions 
and which, thereby, suggest the optimal testing 
strategy, depend on four parameters: P,,, P, , Se, 
and S,. Changes in these parameters alter the 
sizes of the regions depicted. Shapes and general 
relationships among regions do not change. By 
inspection of equations (Appendix B) for these 
curves, we reach the following conclusions 
regarding the effects of changes in these par- 
ameters on choice of testing strategy with the 
smallest bias. 
Increases in P, for constant PO (i.e. increases 
in treatment effectiveness) and increases in PO 
for constant P, - PO (i.e. increases in control 
quit rates with treatment effectiveness left un- 
changed) have the same effects. Both increase 
1 - P,,/l - P, (the value for f toward which all 
curves approach for high values of d) and 
P, - P,,/l -P, (a coefficient for d-’ which 
determines the distance curves deviate from 
f = 1 - PO/1 - P, ). Thus, in effect, the areas 
taken by regions II and III in Fig. 1 and by 
regions III and IV in Fig. 2 expand. That is, 
with higher quit rates, self-report produces less 
bias, for a wider range of possible values for 
d and f, than biochemical testing. 
Increases in test sensitivity S, have slightly 
more complex effects. Increases in S,, with one 
exception, favor strategies which make use of a 
biochemical test. Paradoxically, increases in S, 
expand the area taken by region III in Fig. 2. 
That is, increases in S, expand slightly the range 
of values for f and d over which the no testing 
strategy produces smaller relative biases than 
the strategy which tests self-reported quitters. In 
the former, but not the latter, instance, the 
relative bias is positive in direction. 
Increases in test specificity (S,), without ex- 
ception, favor strategies which make use of a 
biochemical test. In addition, from equation 
(B2), we conclude that increases in S, enlarge 
region I at the expense of region II, in Fig. 3. 
That is, a very specific biochemical test reduces 
the range of values for f and d over which the 
selective test use strategy produces a negative 
relative bias. Again, within region I (Fig. 3), 
universal biochemical testing is required to 
guarantee a trial not biased in favor of the 
experimental treatment. 
DISCUSSION 
The effects of misclassification on obser- 
vational studies or clinical trials have received 
considerable attention [3 1,321. In the context of 
a clinical trial of treatments for smoking, 
misclassification of outcomes can arise from at 
least one of two sources, (1) inaccuracies in 
biochemical tests for smoking, used either to 
confirm self-report or to determine outcomes 
independently of self-report, and (2) misrep- 
resentations, whether intentional or unin- 
tentional, of smoking status at the conclusion of 
study. We developed an algebraic model to 
examine the biases which result from these 
sources of misclassification [33]. 
Table 4 summarizes some principal findings 
from the model. In general, in the presence of 
equivalent treatments, a trial which uses self- 
report or which tests self-reported quitters is 
positively biased; the magnitude of the bias is 
lower in the latter instance. In the absence of 
deceptive self-report, a trial which tests self- 
reported quitters or which tests all subjects is 
negatively biased; the magnitude of the bias is 
lower in the former instance. In the presence of 
equivalent deception rates in the control and 
experimental groups, a trial is always biased in 
a negative direction. Whether a biochemical test 
increases or decreases the magnitude of this bias 
depends on the precise relationships between 
characteristics of the test (i.e. sensitivity and 
specificity) and the deception rate. 
The model also demonstrates that in the 
presence of a truly efficacious treatment, but 
with differential deception in control and experi- 
mental groups, increased sensitivity and 
specificity of a biochemical test, when used to 
validate the statements of self-reported quitters, 
have opposing effects on the bias. The model 
identifies the point beyond which, for a given 
test specificity, further improvements in test 
sensitivity result only in progressive bias in a 
negative direction (inequality 6). 
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Finally, the model shows that the role bio- 
chemical tests should play in clinical trials of 
treatments for smoking depends on the quan- 
titative relationships among deception rates and 
test characteristics. For one specific set of values 
for P, , PO, S,, and S,, Figs l-3 display graph- 
ically which one of two paired designs, for given 
levels of deception in control or experimental 
groups, results in a trial least biased. Similar 
figures can be generated, for different values for 
P, , P,,, S,, and S,, from equations provided in 
Appendix B. These figures emphasize that any 
judgement regarding the proper role of bio- 
chemical testing implies a quantitative state- 
ment regarding the magnitudes of deception 
in both the experimental and control groups. 
Unfortunately, our current state of knowledge 
permits only very imprecise estimates of the 
deception which occurs in actual practice 
(Tables l-3). 
We provide an example of application of 
these results during the design of an actual 
clinical trial of a treatment for smoking. Two 
biochemical tests were considered. The two tests 
differed in sensitivity, cost, and ease of adminis- 
tration. We used expression (3) to estimate the 
impact of each test on the amount of bias 
expected from a trial which used an imperfect 
test to confirm nonsmoking in se!f-reported 
quitters. For this purpose, we represented the 
expected effectiveness of the experimental inter- 
vention and the expected degree of deceptive 
self-report with the following parameters: 
PO = 0.10, P, = 0.20, d = 0.10, and f = 2. Under 
these conditions, the more expensive and accu- 
rate test (S, = 0.98, S, = 0.98) would yield an 
observed treatment effect 1% smaller than the 
true treatment effect. The less expensive and less 
sensitive test (S, = 0.90, S,, = 0.98) would yield 
an observed treatment effect 5% larger than the 
true treatment effect. We concluded that the less 
expensive test would satisfy the needs of a trial 
which aimed to limit the bias to 5%. 
In summary, the magnitude of deception, the 
determinants of deception, and the responsive- 
ness of deception to changes in experimental 
protocol are uncertain. With this uncertainty, 
biochemical assessments of treatment outcomes 
from clinical trials must continue to play an 
important role, despite the risk of bias directed 
against observation of true treatment effects. 
Future trials should assess the value of biochem- 
ical tests in the context of expected deception 
rates in different treatment groups. More work 
is needed to improve the validity of self-reports 
C.E. 42/3-e 
of s&oking and to understand deception among 
smokers 8s a phenomenon which not only 
complicates assessment ‘of treatment programs 
for smoking, but may also relate with other 
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APPENDIX A 
Consider clinical trial participants who distribute in the 
manner depicted in Table Al. By definition, the true treat- 
ment effect is 
(Pi, + F,,) -(P*, + F22) = P, - PO. 
The apparent treatment effect produced under conditions 
of deception is 
(PI,+ P,, + p,, + P14) - (P21+ P22 + Pu + P24) 
= P, - PO + (P,, + P,.,) - (Prr + Pr.,). (Al) 
But, by definition, 
d= P23 + P24 
P23 + PM + Pz + P26 
and 
f.d= PI3 + PM 
pi3 + PM + p,, + PI,’ 
642) 
(A3) 
Substituting expressions (A2) and (A3) into (Al), the appar- 
ent treatment effect produced under conditions of deception 
then becomes 
(PI--~,)+d.(f(l-P,)-(l-P,)), 
the absolute bias 
d.(f(l -PI)-(1 -PO)), 
and the relative bias 
(A4) 
d.(f(l-P,)-(l-p,)) 
P, -PO . (A5) 
The apparent treatment effect, when all participants are 
classified by a biochemical test for smoking, is 
(Pll + p,, + P,,) - (P*, + p23 + P*s) 
= (P,, + (1 -P,) - p,, - P16) 
- (P,, + (1 -PO) - P24 - P26). (A6) 
By definition, the sensitivity (5,) of the biochemical test is 
PM PM p24 P26 =- =- =- 
PI, + PM p,, + PM p23 + % p25 + pm 
= S, (A7) 
and the specificity (5,) 
PI, p2, 
P,,+P,,=p,,=p,p. W) 
Expressing P,, and P2, in terms of S (expression A8) and 
P,,, P,,, Pz4, and Pg6 in terms olr 5, (expression A7), 
expression (A6), the apparent treatment effect, becomes 
(PI - P&S, + 5, - l), 
the absolute bias 
(PI - P,)(S, + 5, - 1) - (PI -P,), 
and the relative bias 
(A9) 
s, + s, - 2 = -((I - s,, + (1 - S,)). (AlO) 
Finally, the apparent treatment effect, when self-reported 
quitters are classified by the biochemical test and when 
self-reported smokers are classified as smokers, is 
(Pll + Pll) -(P*, + P*r) 
= (Pll + (Pu + P,,) - P,,) 
- (P2, + (P23 + P,) - %). (All) 
Expressing (Pll + PJ in terms off and d (expression A3), 
(P13 + Pz4) in terms of d (expression A2), P,, and P2, in 
terms of S, (expression A8) and P,, and Pa in terms of S, 
(expression A7), expression (Al 1), the apparent treatment 
effect, becomes 
(P, - P,)S, + d.(f(l -Pi) - (1 - P,))(l -Se), 
the absolute bias 
d*(f(l -P,) - (1 -P,))(l -S,) - (P, -P,)(l-S,), (A12) 
and the relative bias 
d.(f(l -P,)-(1 -P&s - (1 -S,). (A13) 
1 0 
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Table Al. Cell probabilities for subjects enrolled in a clinical trial of treatments 
for smoking and class&d according to true outcome, self-reported outcome, and 
biochemical test results 
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True quitter True smoker 
self-reported self-reported 
quitter smoker 
Neg Pos Neg Pos Neg Pos Total 
Experimental group P,, P,, P,, Pi, P,, Pi, 1.00 
Control group PZI Pu P23 P24 P2s Px 1.00 
Neg = biochemical test indicates nonsmoking. Pos = biochemical test indicates 
smoking. 
APPENDIX B 
The curves which separate Figs 1-3 into regions derive from 
inequalities which make use of expressions (I), (2), and (3). 
The inequality 
iexpression A51 < lexpression AlO), 
d.(fyyl-po)) <I-((l-Sp)+(l_Se))I 
I 0 
is used to derive the curves which separate Fig. 1 into 
regions: 
region I from II, 
f=S+((l -&,)+(I -Se))+$$ 
I I 
region II from III, 
f=z, and 
I 
region III from IV, 
f=S -((l-sp)+(l-&))~~. W) 
I I 
The inequality 
I expression A5 ( < I expression A 13 I, 
d.(f(l-P,)-(l--o)) 
PI - PO 
< d.(f(l -P,)-(1 -P,)g+ (1 -q 
I 0 
is used to derive the curves which separate Fig. 2 into 
regions: 
region I from II, 
f=-..- --- l-Po+l-spP,-Pol 
1 - P, 1 - s, 1 - P, d’ 
region II from III, 
1 - PO f=- I-S, P, - PO 1 -- 
I- P, + 1 + (1 - S,) 1 - P, d’ 
region III from IV, equation (BI) and 
region IV from V, 
I-P, l-S,P,-PO1 f =-____. 
I-P, S, 1 -P, d 
The inequality 
iexpression Al01 < Iexpression A131, 
I-((1 -S,)+(l -&))I 
@2) 
< d(f(l -P,)-(1 -PO))-!& (1 - Sp) 
I 0 
is used to derive the curves which separate Fig. 3 into 
regions: 
region I from II, equation (BZ), and 
region II from III, 
I-P, P,-PO1 f=_---* 
1 -P, l-P,d 
